TY - JOUR
T1 - Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
AU - Raggi, Chiara
AU - Taddei, Maria Letizia
AU - Sacco, Elena
AU - Navari, Nadia
AU - Correnti, Margherita
AU - Piombanti, Benedetta
AU - Pastore, Mirella
AU - Campani, Claudia
AU - Pranzini, Erica
AU - Iorio, Jessica
AU - Lori, Giulia
AU - Lottini, Tiziano
AU - Peano, Clelia
AU - Cibella, Javier
AU - Lewinska, Monika
AU - Andersen, Jesper B
AU - di Tommaso, Luca
AU - Viganò, Luca
AU - Di Maira, Giovanni
AU - Madiai, Stefania
AU - Ramazzotti, Matteo
AU - Orlandi, Ivan
AU - Arcangeli, Annarosa
AU - Chiarugi, Paola
AU - Marra, Fabio
N1 - Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
PY - 2021
Y1 - 2021
N2 - BACKGROUND & AIMS: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.METHODS: The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters.RESULTS: Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence.CONCLUSIONS: The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features.LAY SUMMARY: The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.
AB - BACKGROUND & AIMS: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.METHODS: The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters.RESULTS: Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence.CONCLUSIONS: The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features.LAY SUMMARY: The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.
KW - Animals
KW - Bile Duct Neoplasms/drug therapy
KW - Carcinogenesis/drug effects
KW - Cell Line, Tumor
KW - Cholangiocarcinoma/drug therapy
KW - Electron Transport Complex II/metabolism
KW - Epithelial-Mesenchymal Transition/drug effects
KW - Gene Silencing
KW - Humans
KW - Indoles/administration & dosage
KW - Male
KW - Metformin/administration & dosage
KW - Mice
KW - Mice, Inbred NOD
KW - Mice, SCID
KW - Mitochondria/metabolism
KW - Neoplastic Stem Cells/metabolism
KW - Oxidative Phosphorylation/drug effects
KW - Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/antagonists & inhibitors
KW - Phenotype
KW - Progression-Free Survival
KW - Propanols/administration & dosage
KW - Signal Transduction/drug effects
KW - Transfection
KW - Treatment Outcome
KW - Tumor Burden/drug effects
KW - Xenograft Model Antitumor Assays
U2 - 10.1016/j.jhep.2020.12.031
DO - 10.1016/j.jhep.2020.12.031
M3 - Journal article
C2 - 33484774
SN - 0169-5185
VL - 74
SP - 1373
EP - 1385
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 6
ER -